MedTrace Logo

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

NCT05123209 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-11-17

No results posted yet for this study

Summary

This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.

Conditions

Interventions

BIOLOGICAL

IM83 CAR-T cells

3×10\^9 CAR-T cells

COMBINATION_PRODUCT

The second-line treatment of liver cancer

approved by NMPA

Sponsors & Collaborators

  • Beijing Immunochina Medical Science & Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-24
Primary Completion
2023-08-30
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05123209 on ClinicalTrials.gov